Quetzaltenango, Guatemala Clinical Trials

A listing of Quetzaltenango, Guatemala clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

Centro Regional de Sub Especialidades Medicas SA ( Site 3003)
 (0.7 away) Contact site
  • 175 views
  • 23 Sep, 2021
  • +146 other locations
Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With CVD

This is a pivotal phase 3 study designed to support an indication for the reduction of cardiovascular risk in patients with established CVD and elevated Lp(a)

Novartis Investigative Site
 (0.0 away) Contact site
  • 151 views
  • 23 Sep, 2021
  • +578 other locations
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

advanced cancer
pembrolizumab
cancer of the ovary
mk-3475
measurable disease
Centro Medico Integral De Cancerolog a (CEMIC) ( Site 3002)
 (0.7 away) Contact site
  • 19 views
  • 24 Sep, 2021
  • +150 other locations
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in: participants with esophageal squamous cell carcinoma (ESCC), participants whose tumors express …

pembrolizumab
chemotherapy regimen
squamous cell carcinoma
carcinoma
chemoradiotherapy
Centro Medico Integral De Cancerolog a (CEMIC) ( Site 0123)
 (0.7 away) Contact site
  • 32 views
  • 23 Sep, 2021
  • +152 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC). The primary hypothesis is that pembrolizumab + chemoradiotherapy is superior to placebo + chemoradiotherapy with respect to bladder intact event-free survival.

pembrolizumab
fluorouracil
cancer
bladder tumor
bladder cancer
Centro Medico Integral De Cancerolog a (CEMIC) ( Site 0144)
 (0.7 away) Contact site
  • 76 views
  • 17 Sep, 2021
  • +113 other locations
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus concurrent chemoradiotherapy compared to placebo plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer. The primary hypotheses are that pembrolizumab plus concurrent chemoradiotherapy is superior to placebo plus concurrent chemoradiotherapy with respect to progression-free …

pembrolizumab
squamous cell carcinoma
cancer
carcinoma
chemoradiotherapy
Centro Medico Integral De Cancerolog a (CEMIC) ( Site 0322)
 (0.7 away) Contact site
  • 87 views
  • 23 Sep, 2021
  • +165 other locations
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902) or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib Versus Pembrolizumab and Lenvatinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is …

lenvatinib
pembrolizumab
carcinoma
systemic therapy
clear cell renal cell carcinoma
Centro Regional de Sub Especialidades Medicas SA ( Site 0704)
 (0.7 away) Contact site
  • 3 views
  • 23 Sep, 2021
  • +92 other locations